Preparation and application of soluble oligodeoxyribonucleotide microneedles for whitening and freckle removal

The whitening and freckle removal soluble microneedle patch prepared by combining oligodeoxyribonucleotides and other components has solved the problem of easy delivery of the matrix material and unstable release of active ingredients, and achieved effective whitening and freckle removal effects and sustained release characteristics. Reduces the risk of skin irritation.

CN118948650BActive Publication Date: 2024-12-06TIANJIN SAIMENG BIOTECHNOLOGY CO LTD +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411418994.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-10-12
Publication Date
2024-12-06
Estimated Expiration
2044-10-12

AI Technical Summary

Technical Problem

The matrix materials in existing whitening and freckle removal products are prone to dehysteresis, and the effective ingredients cannot effectively play a role in whitening and freckle removal, which may cause dermatitis or anti-black phenomenon. Moreover, the release rate of active ingredients of traditional soluble microneedles is unstable, resulting in unsatisfactory treatment effect.

Method used

Using a soluble oligodeoxyribonucleotide microneedle for whitening and freckle removal, the oligodeoxyribonucleotide, Decapeptide-12, isoformis, L-cysteine ​​and ring (proline-cheese) Combining components such as amino acid) to prepare hydrogel microspheres and microneedle auxiliary materials to form soluble microneedle patches, spray drying technology to prepare needle tips and substrates to improve the drug load and sustained release effect.

Benefits of technology

It achieves the promotion of skin metabolism and inhibits tyrosinase activity, blocks the formation of melanin, significantly reduces skin pigmentation, has good whitening and freckle removal effects, and improves the drug loading and sustained release characteristics, reducing the skin Stimulus risk.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948650B_ABST
    Figure CN118948650B_ABST
Patent Text Reader

Abstract

The present invention provides an active composition, comprising the following components by weight: 0.1-2 parts of oligodeoxyribonucleotides, 0.01-1 parts of Decapeptide-12, 0.005-0.5 parts of iso-nelumboside, 0.1-10 parts of L-cysteine, and 0.05-5 parts of cyclo(proline-tyrosine). The present invention prepares the active composition into hydrogel microspheres, and then combines them with a microneedle matrix to prepare a whitening and freckle-removing soluble sustained-release microneedle patch with a high drug loading, and the microneedle patch has good skin whitening, fading / removing freckles, and sustained-release effects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical aesthetics technology, and in particular relates to the preparation and application of a soluble oligodeoxyribonucleotide microneedle for whitening and removing spots. Background Art

[0002] With the increase of age and the influence of the external environment, the synthesis of melanin in the surface layer of the skin increases and the elimination slows down, thus forming brown or black pigmentation patches. Pigmentation spots often occur on the cheeks and forehead, seriously affecting the beauty of the face. Currently, the widely used whitening and spot-lightening products mainly achieve the whitening and spot-lightening effect by adding skin whitening agents into the products. They target melanocytes or tyrosinase, and reduce melanin deposition by inhibiting cell growth, reducing tyrosinase activity, and blocking the synthesis and migration of melanin. However, the skin is a complex tissue structure. On the one hand, the stratum corneum, as the main barrier, can inhibit most effective water-soluble ingredients from penetrating into the subcutaneous tissue to exert their effects; on the other hand, age and the external environment can cause collagen / elastin deficiency in the skin, slowing down skin metabolism, resulting in the inability of nutrients in smear-type cosmetics to be effectively absorbed by the skin, and it is difficult to penetrate into the skin to exert their effects.

[0003] Surgical cosmetology uses micro-injection technology to directly deliver active substances to the required parts of the skin (granular layer, mesoderm, dermis, etc.). Compared with traditional external whitening and freckle removal products, the effect is more obvious. However, micro-injection technology has relatively high requirements for the operator, and often causes pain, redness and swelling due to inaccurate measurement and improper operation. In addition, this technology has high requirements for the operation environment. Compared with other beauty products, it has the disadvantages of high risk, high cost, and poor patient compliance. Microneedle array (microneedle technology) is an emerging transdermal drug delivery technology. Without touching the pain nerves, it can pierce the stratum corneum of the skin and effectively deliver active substances to the subcutaneous layer. Due to the characteristics of safety, high transdermal absorption, low pain, and good patient compliance, microneedle technology has been favored by the medical beauty and plastic surgery industries. However, due to the shortcomings of solid microneedles, hollow microneedles, and coated microneedles, such as small drug loading, difficult measurement, poor accuracy, and easy and rapid closure of micropores, the treatment effect of microneedle beauty products is not ideal. At the same time, due to the immaturity of the preparation process, there are still safety hazards such as tiny solid and metal fragments breaking and remaining in the skin. In order to overcome the above-mentioned shortcomings of traditional cosmetics and solid microneedles, people have innovated and invented soluble microneedle technology, which is a technology that solidifies the active ingredients into a microneedle structure. When the microneedle body penetrates the skin, the microneedle body dissolves by itself, improving the transdermal delivery efficiency of macromolecules and water-soluble drugs. In addition, after soluble microneedles penetrate the skin, they can form self-repairing microchannels, using the natural healing ability of wounds, and will not make the skin harden and shrink. Compared with traditional solid microneedles, soluble microneedles are easy to operate, safe, less irritating, powerful, and long-lasting, and have unlimited market potential.

[0004] The efficacy of soluble microneedles is related to the matrix material used and its additional ingredients. The matrix material is easily soluble in water, making the soluble microneedles susceptible to moisture in the air and deliquescing, which not only affects the mechanical strength of the microneedles, but also causes drug degradation and deterioration. Improper combination of effective ingredients not only fails to achieve the effect of whitening and removing spots, but also induces dermatitis and anti-blackening. At the same time, after the traditional soluble microneedles penetrate the skin, the microneedle matrix material absorbs tissue fluid in the skin and dissolves quickly, resulting in a very fast release rate of active ingredients in the skin. Too much active ingredients in the microneedles will increase the incidence of adverse reactions; insufficient active ingredients will cause the efficacy results to be unclear. These deficiencies have seriously affected the popularization and application of microneedles. Summary of the invention

[0005] In view of this, the present invention aims to propose a preparation and application of a soluble oligodeoxyribonucleotide microneedle for whitening and freckle removal, so as to solve the problem that the matrix material is easy to deliquesce and the effective ingredients not only fail to play a role in whitening and freckle removal, but also induce dermatitis and cause darkening.

[0006] To achieve the above object, the technical solution of the present invention is achieved as follows:

[0007] The first aspect of the present invention provides an active composition, comprising the following components in parts by weight: 0.1-2 parts of oligodeoxyribonucleotides, 0.01-1 parts of Decapeptide-12, 0.005-0.5 parts of iso-nelumboside, 0.1-10 parts of L-cysteine, and 0.05-5 parts of cyclo(proline-tyrosine).

[0008] Furthermore, the active composition comprises the following components in parts by weight: 0.5-1 part of oligodeoxyribonucleotide, 0.05-0.5 part of Decapeptide-12, 0.05-0.1 part of isohexanthoside, 1-5 parts of L-cysteine, and 0.1-1 part of cyclo(proline-tyrosine).

[0009] Furthermore, the molecular weight of the oligodeoxyribonucleotide is 32 kDa-300 kDa, preferably 65 kDa-160 kDa.

[0010] The second aspect of the present invention provides a hydrogel microsphere, comprising the active composition of the first aspect of the present invention and a cross-linking agent;

[0011] The weight ratio of the active composition to the cross-linking agent is 1:0.1-1;

[0012] The cross-linking agent consists of polyoxymethylene alcohol, polyvinyl alcohol, gelatin or sodium alginate.

[0013] The third aspect of the present invention provides a soluble microneedle patch, comprising a needle tip and a substrate, wherein the needle tip is prepared from the hydrogel microspheres and microneedle excipients described in the second aspect of the present invention;

[0014] The mass ratio of the hydrogel microspheres to the microneedle auxiliary materials is 0.1-1:3.

[0015] Furthermore, the mass ratio of the hydrogel microspheres to the microneedle excipients is 0.1:3.

[0016] Furthermore, the mass ratio of the hydrogel microspheres to the microneedle excipients is 0.5:3.

[0017] Furthermore, the mass ratio of the hydrogel microspheres to the microneedle excipients is 1:3.

[0018] Further, the microneedle auxiliary material includes the following components in parts by weight: 5-20 parts of polyvinyl alcohol, 1-10 parts of polyvinyl pyrrolidone, 2-10 parts of glycerol, 5-15 parts of dextran, and 2-10 parts of hydroxypropyl cellulose or carboxymethyl cellulose;

[0019] Preferably, the microneedle excipient comprises the following components in parts by weight: 7-10 parts of polyvinyl alcohol, 3-5 parts of polyvinyl pyrrolidone, 8-10 parts of glycerol, 8-10 parts of dextran, and 5-7 parts of hydroxypropyl cellulose or carboxymethyl cellulose.

[0020] Furthermore, the glucan (dextran) is alpha glucan, and its molecular weight is 200kDa-2000kDa, preferably 500kDa-1000kDa.

[0021] Furthermore, the needle tip is conical or quasi-conical.

[0022] Furthermore, the substrate includes 0.1-1 parts of cross-linked hyaluronic acid, 0.05-0.5 parts of glycerol, 0.05-0.5 parts of polyvinyl alcohol, and 0.05-0.5 parts of hydroxypropyl cellulose or carboxymethyl cellulose.

[0023] The fourth aspect of the present invention provides a method for preparing the soluble microneedle patch according to the third aspect of the present invention, comprising the following steps:

[0024] S1: preparation of needle tip, S2: preparation of substrate;

[0025] The S1 specifically includes the following steps:

[0026] S11: Preparation of the active composition: weigh the following components according to the following weight ratio: 0.1-2 parts of oligodeoxyribonucleotide, 0.01-1 parts of Decapeptide-12, 0.005-0.5 parts of iso-nelumboside, 0.1-10 parts of L-cysteine, and 0.05-5 parts of cyclo(proline-tyrosine), mix the above components, add physiological saline to dissolve, filter and sterilize, and obtain the active composition;

[0027] S12: Preparation of hydrogel microspheres: dissolving the active composition prepared in S11 and the cross-linking agent in water according to a certain proportion, and spray drying to obtain hydrogel microspheres;

[0028] S13: Preparation of microneedle excipients: Weigh the following components in the following weight ratio: 5-20 parts of polyvinyl alcohol, 1-10 parts of polyvinyl pyrrolidone, 2-10 parts of glycerol, 5-15 parts of dextran, and 2-10 parts of hydroxypropyl cellulose or carboxymethyl cellulose, mix the above components, add physiological saline, stir and dissolve at 80° C. for 30 minutes, and obtain a microneedle excipient solution;

[0029] S14: mixing the hydrogel microspheres and microneedle auxiliary material solution obtained in S12 and S13 in proportion to obtain a needle tip solution, pouring the needle tip solution into a microneedle mold, and applying pressure to fill the needle holes of the microneedle mold with the needle tip solution;

[0030] The S2 specifically includes the following steps:

[0031] S21: Weigh the following components in the following weight ratios: 0.1-1 part of cross-linked hyaluronic acid, 0.05-0.5 part of glycerol, 0.05-0.5 part of polyvinyl alcohol, and 0.05-0.5 part of hydroxypropyl cellulose or carboxymethyl cellulose, and mix and dissolve the above components to obtain a base solution;

[0032] S22: evenly coating the base solution on the microneedle mold treated in S1, drying, and demoulding to obtain the microneedle patch.

[0033] Furthermore, the pressure of the pressurization in S14 is 0.03-0.1 MPa;

[0034] The drying conditions in S22 are: temperature of 40±5° C., humidity of 10%±5%, and time of 12±3 h.

[0035] Furthermore, the S12 uses a fully automatic laboratory spray dryer SD-06AG from Labplant, a British company.

[0036] The fifth aspect of the present invention provides the use of the soluble microneedle patch described in the third aspect of the present invention in the preparation of whitening and freckle removal products.

[0037] The composition of the present invention has whitening and freckle removal effects, wherein:

[0038] Oligodeoxyribonudeotide (PDRN), derived from salmon milt, has the effects of improving cell metabolism, shrinking pores, tightening the skin, inhibiting the formation of melanin and whitening the skin.

[0039] Decapeptide-12 is a 10-amino acid decapeptide with strong tyrosinase inhibitory activity. It significantly brightens skin tone and improves skin texture by reducing melanin production.

[0040] Isopalmatin comes from the dried roots and rhizomes of Rheum palmatum L., a plant of the Polygonaceae family. As a natural active substance, it blocks the formation of melanin by inhibiting the activity of tyrosinase in the skin. It also has anti-inflammatory and pain-relieving effects.

[0041] L-cysteine ​​significantly reduces the synthesis of pigments in the skin by inhibiting the activity of histidase in the skin. At the same time, L-cysteine ​​can promote the production of collagen tissue and effectively maintain the elasticity and texture of the skin.

[0042] Cyclo(proline-tyrosine) comes from Corynebacterium tuberculosis stearic acid and is a potent tyrosinase inhibitory compound. It effectively inhibits skin melanin deposition caused by ultraviolet rays, external stimulation, and damage by acting with tyrosinase, thereby producing the effects of removing spots, fading spots, and whitening the skin.

[0043] The above components are used in combination to have a synergistic effect, so that the obtained active composition has excellent skin whitening and spot removal effects.

[0044] Compared with the prior art, the preparation and application of the soluble oligodeoxyribonucleotide microneedles for whitening and removing spots of the present invention have the following advantages:

[0045] (1) The rational combination of active substances in the needle tip described in the present invention can effectively promote skin metabolism, inhibit the activity of tyrosinase in the skin, block the formation of melanin, thereby reducing skin pigmentation, refining skin texture, and playing a role in whitening and removing spots. In addition, in addition to having whitening and spot-lightening, water-retaining and moisturizing effects, PDRN can also improve cell metabolism, promote cell absorption of substances, and improve the whitening and spot-lightening effects of the above-mentioned active substances.

[0046] (2) The microneedle excipients composed of polyvinyl alcohol, polyvinyl pyrrolidone, glycerol and hydroxypropyl cellulose described in the present invention can improve the mechanical properties and physical properties of the soluble microneedles.

[0047] (3) The hydrogel microspheres described in the present invention have the effects of large drug loading and sustained release.

[0048] (4) Compared with traditional whitening products, the whitening and freckle-removing soluble microneedle patch prepared by the present invention has the characteristics of no preservatives added, rapid and complete transdermal absorption, good targeting, large drug loading capacity, and good therapeutic effect, and has a good market application prospect. BRIEF DESCRIPTION OF THE DRAWINGS

[0049] The accompanying drawings constituting a part of the present invention are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. In the accompanying drawings:

[0050] Figure 1 This is a schematic diagram of the soluble microneedle patch described in Examples 1-3 of the present invention;

[0051] Figure 2 Schematic diagram of the soluble microneedle patch described in Example 1 of the present invention;

[0052] Figure 3 for Figure 2 A partial enlarged view of

[0053] Figure 4 is a schematic diagram of the soluble microneedle patch described in Example 2 of the present invention;

[0054] Figure 5 is a schematic diagram of the soluble microneedle patch described in Example 3 of the present invention;

[0055] Figure 6 This is a schematic diagram of a scanning electron microscope of the hydrogel microspheres described in Experimental Example 1 of the present invention;

[0056] Figure 7 This is a graph showing the L-cysteine ​​content of the soluble microneedle patch described in Experimental Example 1 of the present invention;

[0057] Figure 8 The effects of different formulations on cell activity in Experimental Example 2 of the present invention;

[0058] Fig. 9 The effects of different formulations on melanin formation rate in Experimental Example 2 of the present invention;

[0059] Fig.10 This is the effect of different formulations on tyrosinase activity in Experimental Example 2 of the present invention. DETAILED DESCRIPTION

[0060] It should be noted that, in the absence of conflict, the embodiments and features in the embodiments of the present invention can be combined with each other. Unless otherwise defined, the technical terms used in the following embodiments have the same meanings as those generally understood by technicians in the field to which the present invention belongs. The test reagents used in the following embodiments, unless otherwise specified, are all conventional biochemical reagents; the experimental methods, unless otherwise specified, are all conventional methods.

[0061] The present invention will be described in detail below with reference to the accompanying drawings and in conjunction with embodiments. Example 1

[0062] 1. Preparation of needle tip:

[0063] 1.1 Preparation of active composition: Dissolve 0.1 part of PDRN (65kDa-160kDa), 0.01 part of Decapeptide-12, 0.005 part of iso-lotiol, 0.1 part of L-cysteine, and 0.05 part of cyclo(proline-tyrosine) in normal saline and filter through a 0.22um filter membrane;

[0064] 1.2 Preparation of hydrogel microspheres: The active composition prepared above was mixed with a crosslinking agent (polyvinyl alcohol or sodium alginate) at a ratio of 1:0.1, and the liquid raw material was sprayed into a hot drying medium (air) using a fully automatic laboratory spray dryer SD-06AG from Labplant, UK, to convert it into 2 μm hydrogel microspheres;

[0065] 1.3 Preparation of microneedle excipients: Mix 5 parts of polyvinyl alcohol, 1 part of polyvinyl pyrrolidone, 2 parts of glycerol, 5 parts of dextran (500kDa-1000kDa), and 2 parts of carboxymethyl cellulose, add physiological saline, stir and dissolve at 80°C for 30 minutes to obtain a microneedle excipient solution;

[0066] 1.4 The hydrogel microspheres and microneedle excipients were mixed in a weight ratio of 0.1:3 to obtain a needle tip solution, and the needle tip solution was poured into the microneedle mold and pressurized to 0.05 MPa to fill the needle holes of the microneedle mold with the needle tip solution.

[0067] 2. Preparation of substrate:

[0068] Mix and dissolve 0.1 parts of cross-linked hyaluronic acid, 0.05 parts of glycerol, 0.05 parts of polyvinyl alcohol and 0.05 parts of carboxymethyl cellulose to obtain a base solution, and evenly apply the base solution to the microneedle mold treated in step 1, place it in an environment with a temperature of 40±5°C and a humidity of 10%±5%, dry it for 12±3h, and demold it to obtain the soluble microneedle patch. Example 2

[0069] 1. Preparation of needle tip:

[0070] 1.1 Preparation of active composition: Dissolve 2 parts of PDRN (65kDa-160kDa), 1 part of Decapeptide-12, 0.5 parts of iso-lotus palmoside, 10 parts of L-cysteine, and 5 parts of cyclo(proline-tyrosine) in normal saline and filter through a 0.22um filter membrane;

[0071] 1.2 Preparation of hydrogel microspheres: The active composition prepared above was mixed with a crosslinking agent (polyvinyl alcohol or sodium alginate) at a ratio of 1:0.1, and the liquid raw material was sprayed into a hot drying medium (air) using a fully automatic laboratory spray dryer SD-06AG from Labplant, UK, to convert it into 2 μm hydrogel microspheres;

[0072] 1.3 Preparation of microneedle excipients: Mix 5 parts of polyvinyl alcohol, 1 part of polyvinyl pyrrolidone, 2 parts of glycerol, 5 parts of dextran (500kDa-1000kDa), and 2 parts of carboxymethyl cellulose, add physiological saline, stir and dissolve at 80°C for 30 minutes to obtain a microneedle excipient solution;

[0073] 1.4 The hydrogel microspheres and the microneedle excipients were mixed in a weight ratio of 1:3 to obtain a needle tip solution, and the needle tip solution was poured into the microneedle mold and pressurized to 0.05 MPa to fill the needle holes of the microneedle mold with the needle tip solution.

[0074] 2. Preparation of substrate:

[0075] Mix and dissolve 1 part of cross-linked hyaluronic acid, 0.5 part of glycerol, 0.5 part of polyvinyl alcohol and 0.5 part of carboxymethyl cellulose to obtain a base solution, and evenly apply the base solution to the microneedle mold treated in step 1, place it in an environment with a temperature of 40±5°C and a humidity of 10%±5%, dry it for 12±3h, and demold it to obtain the soluble microneedle patch. Example 3

[0076] 1. Preparation of needle tip:

[0077] 1.1 Preparation of active composition: Dissolve 1 part of PDRN (65kDa-160kDa), 0.1 part of Decapeptide-12, 0.05 part of iso-lotiol, 1 part of L-cysteine, and 0.5 part of cyclo(proline-tyrosine) in normal saline and filter through a 0.22um filter membrane;

[0078] 1.2 Preparation of hydrogel microspheres: The active composition prepared above was mixed with a crosslinking agent (polyvinyl alcohol or sodium alginate) at a ratio of 1:0.1, and the liquid raw material was sprayed into a hot drying medium (air) using a fully automatic laboratory spray dryer SD-06AG from Labplant, UK, to convert it into 2 μm hydrogel microspheres;

[0079] 1.3 Preparation of microneedle excipients: Mix 10 parts of polyvinyl alcohol, 5 parts of polyvinyl pyrrolidone, 6 parts of glycerol, 10 parts of dextran (500kDa-1000kDa), and 6 parts of carboxymethyl cellulose, add physiological saline, stir and dissolve at 80°C for 30 minutes to obtain a microneedle excipient solution;

[0080] 1.4 The hydrogel microspheres and the microneedle excipients were mixed in a weight ratio of 0.5:3 to obtain a needle tip solution, and the needle tip solution was poured into the microneedle mold and pressurized to 0.05 MPa to fill the needle holes of the microneedle mold with the needle tip solution.

[0081] 2. Preparation of substrate:

[0082] Mix and dissolve 0.5 parts of cross-linked hyaluronic acid, 0.2 parts of glycerol, 0.2 parts of polyvinyl alcohol and 0.2 parts of carboxymethyl cellulose to obtain a base solution, and evenly apply the base solution to the microneedle mold treated in step 1, place it in an environment with a temperature of 40±5°C and a humidity of 10%±5%, dry it for 12±3h, and demold it to obtain the soluble microneedle patch.

[0083] Experimental Example 1

[0084] Preparation of hydrogel and detection of encapsulation efficiency and sustained release effect of microneedle patch

[0085] The encapsulation efficiency of the hydrogel microspheres and the sustained release effect of the microneedle patch were detected using L-cysteine ​​in the active composition as an indicator.

[0086] (1) Weigh 20 mg of the hydrogel microspheres prepared in Example 2 and dissolve them in 5 ml of a phosphate buffer solution with a pH of 7.4. After they are completely dissolved, take 0.1 ml of the liquid and measure the absorbance of the blank tube, the standard tube, and the measurement tube at a wavelength of 600 nm according to the method of the cysteine ​​kit (micro method). Substitute the absorbance into the formula listed in the kit to calculate the cysteine ​​content, and then use the following formula to calculate the encapsulation efficiency of the hydrogel microspheres:

[0087] ;

[0088] Table 1 Hydrogel microsphere encapsulation efficiency test

[0089]

[0090] It can be seen from Table 1 that the hydrogel microspheres prepared in the present application have a high encapsulation rate, indicating that the hydrogel microspheres prepared by the spray drying method have the characteristics of high drug loading.

[0091] (2) Three healthy mice were selected, anesthetized and killed, and the hair on the back was shaved with an electric shaver. Then, a piece of hairless back skin was cut with scissors, and the fat on the inside was shaved clean. The microneedle patch prepared in Example 2 was applied to the skin according to the method of use, and the inside of the skin was placed on a dissolution cup filled with pH 7.4 phosphate buffer. At 25°C, the dissolution cup under the skin was replaced every 2 hours, and the cysteine ​​content in the dissolution cup was detected every 2 hours using a cysteine ​​kit to determine the sustained release effect of the soluble microneedle patch.

[0092] Depend on Figure 7 As shown, the microneedle patch can continuously release cysteine ​​within 12 hours and maintain the stability of its solution concentration, indicating that the microneedle has a good sustained-release effect.

[0093] Experimental Example 2

[0094] Verify the effect of the obtained active composition on human epidermal melanocytes

[0095] In order to verify the effectiveness of the active compositions of Examples 1, 2, and 3, comparative examples 1, 2, 3, 4, and 5 were designed using the active composition obtained in Example 2 as a template;

[0096] The active composition of Comparative Example 1: 1 part of Decapeptide-12, 0.5 part of iso-lotalcohol, 10 parts of L-cysteine, and 5 parts of cyclo(proline-tyrosine);

[0097] The active composition of Comparative Example 2: 2 parts of PDRN (65kDa-160kDa), 0.5 parts of iso-lotaluolamine, 10 parts of L-cysteine, and 5 parts of cyclo(proline-tyrosine);

[0098] The active composition of Comparative Example 3: 2 parts of PDRN (65kDa-160kDa), 1 part of Decapeptide-12, 10 parts of L-cysteine, and 5 parts of cyclo(proline-tyrosine);

[0099] The active composition of Comparative Example 4: 2 parts of PDRN (65kDa-160kDa), 1 part of Decapeptide-12, 0.5 parts of iso-lotus palm glycoside, and 5 parts of cyclo(proline-tyrosine);

[0100] The active composition of Comparative Example 5: 2 parts of PDRN (65kDa-160kDa), 1 part of Decapeptide-12, 0.5 parts of isohexanthophyllotoxin, and 10 parts of L-cysteine.

[0101] The active compositions of Comparative Examples 1-5 and Examples 1-3 were respectively prepared into 10 mg / mL solutions for later use, and marked in sequence as groups a, b, c, d, e, f, g, and h.

[0102] Human epidermal melanocytes (purchased from Wuhan Pronocell Life Science Co., Ltd.) were cultured in DMEM medium containing 5% fetal bovine serum. When the cell density reached 2×10 6 After that, the cells were inoculated in 6-well plates and divided into 10 groups, namely, normal group, model group, a (Comparative Example 1), b (Comparative Example 2), c (Comparative Example 3), d (Comparative Example 4), e (Comparative Example 5), f (Example 1), g (Example 2), and h (Example 3). When the cells grew to 80%, the cells in the other groups except the normal group were irradiated with ultraviolet light at 0.2 J / cm 2 UVA (365nm), irradiate for 30min every 24 hours, add active composition (the final concentration of each composition is 50μg / ml) after each irradiation, and place in 37℃, 5% CO2 incubator for culture. After 48 hours, the MTT method was used to determine the effect of each composition on cell activity; three days after the cells were treated as above, the cells were collected and added with 500μL NaOH (1M containing 10% dimethyl sulfoxide) solution, and the melanin particles were completely dissolved in a 65℃ water bath, and the melanin formation rate was measured by a microplate reader at 470nm; the treated cells were collected, washed twice with PBS, centrifuged at 1000rpm for 5min, and the cell pellet was set aside for use, 1mL 0.5% sodium deoxycholate was added to the pellet, placed at 0℃ for 15min, and then 3mL 0.1% L-dopa (pH6.8) phosphate buffer was added and placed in a 37℃ water bath, and the initial 0min and 10min absorbance values ​​were detected at 475nm, and the relative activity of tyrosinase in each treatment group was calculated.

[0103] The effects of different prescriptions on cell activity are shown in Figure 8 . (Note: * indicates that compared with the normal group, **p<0.01 has a very significant difference compared with the normal group; # indicates that compared with the model group, ##p<0.01 has a very significant difference compared with the model group, ###p<0.001 has a very significant difference compared with the model group; $ indicates that compared with the Example 1 group, $p<0.05 has a significant difference between the two groups, $$p<0.01 has a very significant difference between the two groups; + indicates that compared with the Example 2 group, +p<0.05 has a significant difference between the two groups, ++p<0.01 has a very significant difference between the two groups; & indicates that compared with the Example 3 group, &p<0.05 has a significant difference between the two groups, &&p<0.01 has a very significant difference between the two groups)

[0104] The effects of different prescriptions on melanin formation rate are shown in Fig. 9. (Note: * indicates that compared with the normal group, **p<0.01 has a very significant difference compared with the normal group; # indicates that compared with the model group, ##p<0.01 has a very significant difference compared with the model group, ###p<0.001 has a very significant difference compared with the model group; $ indicates that compared with the Example 1 group, $p<0.05 has a significant difference between the two groups, $$p<0.01 has a very significant difference between the two groups; + indicates that compared with the Example 2 group, +p<0.05 has a significant difference between the two groups, ++p<0.01 has a very significant difference between the two groups; & indicates that compared with the Example 3 group, &p<0.05 has a significant difference between the two groups, &&p<0.01 has a very significant difference between the two groups)

[0105] The effects of different prescriptions on tyrosinase activity are shown in Fig.10 . (Note: * indicates that compared with the normal group, **p<0.01 has a very significant difference compared with the normal group; # indicates that compared with the model group, ##p<0.01 has a very significant difference compared with the model group, ###p<0.001 has a very significant difference compared with the model group; $ indicates that compared with the Example 1 group, $p<0.05 has a significant difference between the two groups, $$p<0.01 has a very significant difference between the two groups; + indicates that compared with the Example 2 group, +p<0.05 has a significant difference between the two groups, ++p<0.01 has a very significant difference between the two groups; & indicates that compared with the Example 3 group, &p<0.05 has a significant difference between the two groups, &&p<0.01 has a very significant difference between the two groups)

[0106] Depend on Figure 8 , 9 As shown in Figures 1 and 10, long-wave ultraviolet irradiation can significantly increase the activity of human epidermal melanocytes, increase tyrosinase activity, and promote the formation of melanin. The active compositions of Examples 1-3 can effectively inhibit the promoting effect of ultraviolet rays on melanocytes. After administration of different prescriptions, the cell activity is significantly reduced. It can be seen from the graph that the complete prescription can significantly reduce tyrosinase activity and inhibit the formation of melanin. In addition, groups f, g, and h can significantly reduce the activation effect of long-wave ultraviolet rays on melanocytes, effectively reduce tyrosinase activity, and inhibit the formation of melanin. This study shows that the prescription of Example 2 has the best effect in increasing cell activity, inhibiting melanin formation, and reducing tyrosinase activity. The experimental results show that the complete prescription has a significant synergistic effect in increasing cell activity, inhibiting melanin formation, and reducing tyrosinase activity.

[0107] Experimental Example 3

[0108] Study on the whitening and anti-freckle effect of soluble microneedle patch

[0109] The whitening and freckle-removing soluble microneedle patches obtained in Examples 1-3 were functionally evaluated and compared with the corresponding whitening and freckle-removing facial masks (Comparative Example 1) sold on the market.

[0110] 40 female volunteers with healthy skin aged 30 to 50 years old were selected. The exclusion criteria of the subjects met the requirements of GB17149.2-1997 "Diagnostic Criteria and Treatment Principles for Cosmetic Contact Dermatitis", no serious systemic diseases, no immunodeficiency or autoimmune diseases, no active allergic diseases, no history of allergies to skin care cosmetics, no systemic use of hormone drugs and immunosuppressants within 1 month, no pregnancy or lactation, and no ethical taboos. In addition, the subjects all had spots on their faces due to sun exposure, work pressure, age, etc.

[0111] The subjects were randomly divided into 4 groups, with 10 subjects in each group, and the whitening and freckle removal soluble microneedle patches of Examples 1 to 3 of the present invention and the whitening and freckle removal mask of a certain product sold on the market of Comparative Example 1 were used respectively. After cleaning the face in the morning and evening, the subjects used the whitening and freckle removal experimental product on the face twice a day, morning and evening, for 4 consecutive weeks. During the experiment, the subjects could not apply any other cosmetics on the experimental parts.

[0112] 1. Skin brightness detection

[0113] The L* value of the face before the subjects used the samples was tested with a skin colorimeter CL400 (from Courage Khazaka (CK) of Germany) before use, 2 weeks after use, and 4 weeks after use. Skin whiteness (brightness) (L* value): The L* value represents white balance. The larger the value, the more the color tends to be white, and vice versa. The results are shown in Table 2.

[0114] Table 2 Effects on skin brightness

[0115]

[0116] Note: * indicates that the example is compared with the comparative example, *P<0.05 has a significant difference; # indicates that the difference after use is compared with that before use, ##P<0.01 has a very significant difference.

[0117] As shown in Table 2, after using the microneedle patch of the present invention for 4 weeks, the skin chromaticity L* value after use has a very significant increase trend compared with before use in the same group; compared with Comparative Example 1, the skin chromaticity L* values ​​of Examples 2 and 3 after using the microneedle patch of Examples 2 and 3 for 2 weeks are higher than those of Comparative Example 1, but there is no significant difference; after using for 4 weeks, the skin chromaticity L* values ​​of Examples 2 and 3 are significantly higher than those of Comparative Example 1, which is statistically significant. The results show that after using the microneedle patch of the present invention on the face, the skin brightness increases, the skin color gradually becomes whiter, and the color of the spots on the skin gradually becomes lighter.

[0118] 2. Skin moisture content detection

[0119] The skin moisture content of the subjects before and after using the product was tested using a skin moisture tester. The skin moisture content was recorded and tested on the 0th day and the 28th day to evaluate the moisturizing effect of the product. The results are shown in Table 3.

[0120] Table 3 Effects on skin moisture content

[0121]

[0122] Note: # indicates that there is a significant difference between the samples before and after use, ##P<0.01; * indicates that there is a significant difference between the examples and the comparative examples, *P<0.05, and **P<0.01.

[0123] As shown in Table 3, after the microneedle patch of the present invention was administered, the skin moisture content of each group of subjects increased significantly after 4 weeks of use compared with before use. Compared with Comparative Example 1, the skin moisturizing ability of the microneedle patch of the present invention in Examples 2 and 3 is significantly higher than that of other control skin care products used in Comparative Example 1, indicating that the present invention has a good moisturizing function. The data in Table 3 show that after continuous use of the microneedle patch of the present invention for 4 weeks, the skin moisture content increased by more than 44%, further indicating that the present invention has a strong water-locking ability.

[0124] 3. Skin elasticity / skin quality testing

[0125] The skin elasticity / skin texture was tested using a skin moisture tester before and 4 weeks after using the product. The skin texture was divided into 5 levels, namely rough, relatively rough, general, relatively soft, and soft. The results are shown in Table 4.

[0126] Table 4 Effects on skin elasticity / skin quality

[0127]

[0128] As can be seen from Table 4, the skin quality of the 30 subjects was effectively improved after being given the microneedle patches of Examples 1 to 3 of the present invention, and the proportions of soft and fine skin were 4 / 10, 9 / 10, and 7 / 10, respectively, while the proportion of soft and fine skin after being given the comparative example 1 was only 2 / 10. It can be inferred that the present invention has a significant effect in improving skin elasticity and improving skin quality.

[0129] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. An active composition, characterized in that: The invention comprises the following components in parts by weight: 0.1-2 parts of oligodeoxyribonucleotide, 0.01-1 parts of Decapeptide-12, 0.005-0.5 parts of iso-lotalcohol, 0.1-10 parts of L-cysteine ​​and 0.05-5 parts of cyclo(proline-tyrosine).

2. An active composition according to claim 1, characterized in that: The invention comprises the following components in parts by weight: 0.5-1 part of oligodeoxyribonucleotide, 0.05-0.5 part of Decapeptide-12, 0.05-0.1 part of iso-lotalcohol, 1-5 parts of L-cysteine ​​and 0.1-1 part of cyclo(proline-tyrosine).

3. A hydrogel microsphere, characterized in that: Comprising the active composition according to claim 1 or 2 and a cross-linking agent; The weight ratio of the active composition to the cross-linking agent is 1:0.1-1; The cross-linking agent consists of polyoxymethylene alcohol, polyvinyl alcohol, gelatin or sodium alginate.

4. A soluble microneedle patch, characterized in that: It comprises a needle tip and a substrate, wherein the needle tip is prepared from the hydrogel microsphere and microneedle auxiliary material according to claim 3; The mass ratio of the hydrogel microspheres to the microneedle auxiliary materials is 0.1-1:

3.

5. A soluble microneedle patch according to claim 4, characterized in that: The microneedle auxiliary material comprises the following components in parts by weight: 5-20 parts of polyvinyl alcohol, 1-10 parts of polyvinyl pyrrolidone, 2-10 parts of glycerol, 5-15 parts of dextran, and 2-10 parts of hydroxypropyl cellulose or carboxymethyl cellulose.

6. A soluble microneedle patch according to claim 4, characterized in that: The needle tip is conical or quasi-conical.

7. The soluble microneedle patch according to claim 4, characterized in that: The base comprises 0.1-1 part of cross-linked hyaluronic acid, 0.05-0.5 part of glycerol, 0.05-0.5 part of polyvinyl alcohol, and 0.05-0.5 part of hydroxypropyl cellulose or carboxymethyl cellulose.

8. The method for preparing the soluble microneedle patch according to any one of claims 4 to 7, characterized in that: The following steps are involved: S1: preparation of needle tip, S2: preparation of substrate; The S1 specifically includes the following steps: S11: Preparation of the active composition: weigh the following components according to the following weight ratio: 0.1-2 parts of oligodeoxyribonucleotide, 0.01-1 parts of Decapeptide-12, 0.005-0.5 parts of iso-nelumboside, 0.1-10 parts of L-cysteine, and 0.05-5 parts of cyclo(proline-tyrosine), mix the above components, add physiological saline to dissolve, filter and sterilize, and obtain the active composition; S12: Preparation of hydrogel microspheres: dissolving the active composition prepared in S11 and the cross-linking agent in water according to a certain proportion, and spray drying to obtain hydrogel microspheres; S13: Preparation of microneedle excipients: Weigh the following components in the following weight ratio: 5-20 parts of polyvinyl alcohol, 1-10 parts of polyvinyl pyrrolidone, 2-10 parts of glycerol, 5-15 parts of dextran, and 2-10 parts of hydroxypropyl cellulose or carboxymethyl cellulose, mix the above components, add physiological saline, stir and dissolve at 80° C. for 30 minutes, and obtain a microneedle excipient solution; S14: mixing the hydrogel microspheres and microneedle auxiliary material solution obtained in S12 and S13 in proportion to obtain a needle tip solution, pouring the needle tip solution into a microneedle mold, and applying pressure to fill the needle holes of the microneedle mold with the needle tip solution; The S2 specifically includes the following steps: S21: Weigh the following components in the following weight ratios: 0.1-1 part of cross-linked hyaluronic acid, 0.05-0.5 part of glycerol, 0.05-0.5 part of polyvinyl alcohol, and 0.05-0.5 part of hydroxypropyl cellulose or carboxymethyl cellulose, and mix and dissolve the above components to obtain a base solution; S22: evenly coating the base solution on the microneedle mold treated in S1, drying, and demoulding to obtain the microneedle patch.

9. The preparation method according to claim 8, characterized in that: The pressure of the pressurization in S14 is 0.03-0.1MPa; The drying conditions in S22 are: temperature of 40±5° C., humidity of 10%±5%, and time of 12±3 h.

10. Use of a soluble microneedle patch according to any one of claims 4 to 7 in the preparation of whitening and freckle removal products.